The cancer therapeutic agent according to the present invention includes IL-18 and anti-PD-L1 antibody, anti-PD-1 antibody, anti-PD-L2 antibody, anti-CTLA-4 antibody, anti-CD25 antibody, anti-CD33 antibody and anti-CD52 antibody. One or more antibodies selected from the group consisting of:本発明に係る癌治療薬は、IL-18と、抗PD-L1抗体、抗PD-1抗体、抗PD-L2抗体、抗CTLA-4抗体、抗CD25抗体、抗CD33抗体および抗CD52抗体からなる群より選ばれる1以上の抗体と、を有効成分として含有する。